PNC
TEVA icon

Park National Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Park National Corp’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,048
Closed -$266K – 379
2017
Q4 		$266K Sell
14,048
-3,762
-21% -$56.6K 0.01% 291
2017
Q3 		$314K Buy
17,810
+1,008
+6% +$22.7K 0.02% 252
2017
Q2 		$559K Sell
16,802
-1,312
-7% -$40.6K 0.03% 190
2017
Q1 		$582K Buy
18,114
+1,265
+8% +$43.2K 0.04% 182
2016
Q4 		$611K Buy
16,849
+376
+2% +$15K 0.04% 176
2016
Q3 		$758K Sell
16,473
-1,432
-8% -$74.7K 0.05% 166
2016
Q2 		$899K Sell
17,905
-1,048
-6% -$55.8K 0.06% 153
2016
Q1 		$1.01M Sell
18,953
-1,155
-6% -$67.8K 0.07% 144
2015
Q4 		$1.32M Sell
20,108
-543
-3% -$33.6K 0.09% 123
2015
Q3 		$1.17M Sell
20,651
-14
-0.1% -$908 0.08% 124
2015
Q2 		$1.22M Sell
20,665
-430
-2% -$26.5K 0.08% 129
2015
Q1 		$1.31M Sell
21,095
-433
-2% -$25.2K 0.09% 124
2014
Q4 		$1.24M Buy
21,528
+19
+0.1% +$1.06K 0.08% 128
2014
Q3 		$1.16M Sell
21,509
-174
-0.8% -$9.22K 0.08% 124
2014
Q2 		$1.14M Sell
21,683
-120
-0.6% -$6.13K 0.08% 126
2014
Q1 		$1.15M Sell
21,803
-196
-0.9% -$9.06K 0.08% 127
2013
Q4 		$882K Buy
21,999
+910
+4% +$35.8K 0.06% 144
2013
Q3 		$797K Sell
21,089
-4,332
-17% -$169K 0.06% 151
2013
Q2 		$997K Buy
+25,421
New +$990K 0.08% 131

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Park National Corp's TEVA Position: Q1 2018 in Review

Park National Corp sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 14,048 shares — an estimated $266K sold.

Park National Corp first reported a position in TEVA in Q2 2013 and held it in 19 quarters. The position peaked at $1.32M in Q4 2015. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Park National Corp reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Park National Corp sold 14,048 Teva Pharmaceuticals shares in Q1 2018, an estimated $266K.
  • Park National Corp first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Park National Corp's Teva Pharmaceuticals position peaked at $1.32M in Q4 2015.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Park National Corp's 13F filing for Q1 2018, filed 2 Apr 2018.